Evidence map›Paper›PMID 35578378›Full record

ArticleJournal of medical virology2022

Genomics of postvaccination SARS-CoV-2 infections during the Delta dominated second wave of COVID-19 pandemic, from Mumbai Metropolitan Region (MMR), India.

Kayzad Nilgiriwala, Pratibha Kadam, Grishma Patel, Ambreen Shaikh, Tejal Mestry, Smriti Vaswani, Shalini Sakthivel, Aruna Poojary, Bhavesh Gandhi, Seema Rohra and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Kayzad NilgiriwalaThe Foundation for Medical Research, Mumbai, India.ORCID 0000-0002-5458-4916
Pratibha KadamThe Foundation for Medical Research, Mumbai, India.
Grishma PatelThe Foundation for Medical Research, Mumbai, India.
Ambreen ShaikhThe Foundation for Medical Research, Mumbai, India.
Tejal MestryThe Foundation for Medical Research, Mumbai, India.
Smriti VaswaniThe Foundation for Medical Research, Mumbai, India.
Shalini SakthivelThe Foundation for Medical Research, Mumbai, India.
Aruna PoojaryBreach Candy Hospital (BCH) Trust, Mumbai, India.
Bhavesh GandhiBreach Candy Hospital (BCH) Trust, Mumbai, India.
Seema RohraBreach Candy Hospital (BCH) Trust, Mumbai, India.
Zarir UdwadiaBreach Candy Hospital (BCH) Trust, Mumbai, India.
Vikas OswalVikas Nursing Home, Mumbai, India.
Daksha ShahMunicipal Corporation of Greater Mumbai (MCGM), Mumbai, India.
Mangala GomareMunicipal Corporation of Greater Mumbai (MCGM), Mumbai, India.
Kalpana SriramanThe Foundation for Medical Research, Mumbai, India.
Nerges MistryThe Foundation for Medical Research, Mumbai, India.
Foundation for Medical Research · INBreach Candy Hospital · INBrihanmumbai Municipal Corporation · INDr. BMN College of Home Science · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was initiated to understand the proportion of predominant variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in postvaccination infections during the Delta dominated second wave of coronavirus disease 2019 (COVID-19) in the Mumbai Metropolitan Region (MMR) in India and to understand any mutations selected in the postvaccination infections or showing association with any patient demographics. Samples were collected (n = 166) from severe/moderate/mild COVID-19 patients who were either vaccinated (COVISHIELD/COVAXIN-partial/fully vaccinated) or unvaccinated, from a city hospital and from home isolation patients in MMR. A total of 150 viral genomes were sequenced by Oxford Nanopore sequencing and the data of 136 viral genomes were analyzed for clade/lineage and for identifying mutations. The sequences belonged to three clades (21A, 21I, and 21J) and their lineage was identified as either Delta (B.1.617.2) or Delta+ (B.1.617.2 + K417N) or sub-lineages of Delta variant (AY.120/AY.38/AY.99). A total of 620 mutations were identified of which 10 mutations showed an increase in trend with time (May-October 2021). Associations of six mutations (two in spike, three in orf1a, and one in nucleocapsid) were shown with milder forms of the disease and one mutation (in orf1a) with partial vaccination status. The results indicate a trend toward reduction in disease severity as the wave progressed.

Indexed as

COVID-19PandemicsChAdOx1 nCoV-19GenomicsHumansSARS-CoV-2ChAdOx1 nCoV-19epidemiologygeneticsmutationSARS coronavirusvirus classification

Identifiers

PMID35578378
PMCPMC9348366
OpenAlexW4280518129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.